These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31899812)

  • 1. Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Yki-Järvinen H
    Hepatology; 2020 Apr; 71(4):1499-1501. PubMed ID: 31899812
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides.
    Samuel VT; Shulman GI
    N Engl J Med; 2019 Nov; 381(19):1866-1869. PubMed ID: 31693811
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis.
    Apostolopoulou M; Gordillo R; Koliaki C; Gancheva S; Jelenik T; De Filippo E; Herder C; Markgraf D; Jankowiak F; Esposito I; Schlensak M; Scherer PE; Roden M
    Diabetes Care; 2018 Jun; 41(6):1235-1243. PubMed ID: 29602794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism.
    Chen J; Liang B; Bian D; Luo Y; Yang J; Li Z; Zhuang Z; Zang S; Shi J
    Biochem Biophys Res Commun; 2019 Oct; 518(4):691-697. PubMed ID: 31472960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosphingolipids and insulin resistance.
    Aerts JM; Boot RG; van Eijk M; Groener J; Bijl N; Lombardo E; Bietrix FM; Dekker N; Groen AK; Ottenhoff R; van Roomen C; Aten J; Serlie M; Langeveld M; Wennekes T; Overkleeft HS
    Adv Exp Med Biol; 2011; 721():99-119. PubMed ID: 21910085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on lipid species and paediatric nonalcoholic fatty liver disease.
    Mann JP; Feldstein AE; Nobili V
    Curr Opin Clin Nutr Metab Care; 2017 Mar; 20(2):110-116. PubMed ID: 27906700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.
    Rohrbach TD; Asgharpour A; Maczis MA; Montefusco D; Cowart LA; Bedossa P; Sanyal AJ; Spiegel S
    J Lipid Res; 2019 Jul; 60(7):1311-1322. PubMed ID: 31110049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
    Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
    PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver.
    Preuss C; Jelenik T; Bódis K; Müssig K; Burkart V; Szendroedi J; Roden M; Markgraf DF
    Cells; 2019 Mar; 8(3):. PubMed ID: 30909521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis.
    Ejima C; Kuroda H; Ishizaki S
    Physiol Rep; 2016 Nov; 4(21):. PubMed ID: 27821715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
    Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
    J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
    Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Moh Moh MA; Jung CH; Lee B; Choi D; Kim BY; Kim CH; Kang SK; Mok JO
    Diab Vasc Dis Res; 2019 Mar; 16(2):186-195. PubMed ID: 30428692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.